Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 08 Mar 2023
Following a major outbreak involving the use of tear drops in 13 US states, experts are offering advice on how to protect dry eyes.
Read Full NewsThe history of lobotomy shows the risks for limited evidence and oversight, while modern approaches emphasize targeted treatment, informed consent, and rigorous evaluation.
US radiologists vary substantially in their reading of low-dose CT lung cancer screens, highlighting a need for measures to help standardize interpretation.
Researchers compare first-line chemotherapy regimens in older patients with classical Hodgkin lymphoma to assess whether AVD is associated with better outcomes in routine care.
Researchers analyze individual patient data from five randomized phase 3 trials comparing PORT alone vs PORT plus hormone therapy in patients with recurrent prostate cancer.
A new real-world analysis helps clarify the most informative prognostic PSA benchmark in men with metastatic castration-sensitive prostate cancer.
Tissue-free ctDNA may be comparable to tumor-informed assays in detecting molecular residual disease.
1.
In breast-conserving surgery, is micro-CT a useful tool for determining tumor margins?
2.
The most precise research tools for the deadliest blood cancer have been developed.
3.
Cancer Warnings on Alcohol? Surge in GI Illnesses; Swab Detects Kids' Asthma Type
4.
An Intimate Life of Medical Innovation and Charity.
5.
Some triple negative breast cancers might be avoided by longer breastfeeding
1.
Hematopoietic Aging and Functional Blood Health: Mechanisms, Clinical Implications, and Advances
2.
Fc Receptor Mediated Pharmacology of Therapeutic Antibodies
3.
Undersanding Alemtuzumab: What You Need To Know About This Multiple Sclerosis Medication
4.
The Revolutionary Treatment of Hodgkin's Lymphoma: A New Hope for the Future
5.
Intravenous Calcium for Reducing Blood Loss During Cesarean Delivery: A Review of Current Evidence
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
1.
Clinical Insights in Hematology
2.
Managing ALK Rearranged Non-Small Cell Lung Cancer with Lorlatinib - Part I
3.
Recent Data Analysis for First-Line Treatment of ALK+ NSCLC
4.
An Eagles View - Evidence-based discussion on Iron Deficiency Anemia- Further Talks
5.
Guideline Recommendations of Lorlatinib as First-Line Treatment for ALK+ NSCLC
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge